AstraZeneca (AZN) Projected to Post Quarterly Earnings on Thursday

AstraZeneca (NASDAQ:AZN) is projected to post its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect AstraZeneca to post earnings of $1.10 per share and revenue of $14.19 billion for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the prior year, the business posted $0.87 EPS. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. On average, analysts expect AstraZeneca to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $69.86 on Tuesday. The stock has a market cap of $216.64 billion, a P/E ratio of 33.43, a P/E/G ratio of 1.18 and a beta of 0.46. The stock has a 50 day moving average of $67.08 and a two-hundred day moving average of $73.85. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca has a twelve month low of $60.47 and a twelve month high of $87.68.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.